News >

Dual Expression of MYC, BCL2 Associated With Poorer Outcomes in DLBCL

Jason Harris
Published: Friday, May 26, 2017

Nina Wagner-Johnston, MD

Nina Wagner-Johnston, MD

Researchers using cell-of-origin (COO) classification connected dual expression (DE) of the proteins MYC and BCL2 with poorer survival in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL). However, CCO failed to identify a prognostic subgroup, the study’s primary endpoint, according to results published in the Journal of Clinical Oncology.

. She said this is one of the first studies using the Lymph2Cx assay tool and the results produced some unexpected findings and highlight the complexity of prognosticating in DLBCL.

“I don’t think this tells us the tool is not important—I think it is important. But I think the cell of origin is really going to interplay with double expression and double-hit,” she said.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication